Blar i NTNU Open på forfatter "Helland, Åslaug"

Viser treff 1-13 av 13

    • 2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data 

      Ottesen, Jon André; Yi, Darvin; Tong, Elizabeth; Iv, Michael; Latysheva, Anna; Saxhaug, Cathrine; Jacobsen, Kari Dolven; Helland, Åslaug; Emblem, Kyrre E; Rubin, Daniel L.; Bjørnerud, Atle; Zaharchuk, Greg; Grøvik, Endre (Peer reviewed; Journal article, 2023)
      Introduction: Management of patients with brain metastases is often based on manual lesion detection and segmentation by an expert reader. This is a time- and labor-intensive process, and to that end, this work proposes ...

    • Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial 

      Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; ROGG, LOTTE VICTORIA; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug (Peer reviewed; Journal article, 2022)
      The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical ...

    • Concordance between clinical and pathology TNM-staging in lung cancer 

      Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Haram, Per Magnus; Helland, Åslaug; Møller, Bjørn; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Fjellbirkeland, Lars (Peer reviewed; Journal article, 2022)
      Objectives - A prerequisite for utilizing the tumour, lymph-nodes, and metastases (TNM) for the staging of lung cancer patients is a high quality of the reported data on which the staging is based. The aim of this study ...

    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; CAMERON, MARTE; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn (Peer reviewed; Journal article, 2022)
      Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed ...

    • Increase in curative treatment and survival of lung cancer in Norway 2001-2016 

      Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Grimsrud, Tom Kristian; Haram, Per Magnus; Helbekkmo, Nina; Helland, Åslaug; Hjelde, Harald Harris; Jakobsen, Bjørn; Møller, Bjørn; Petersen, Martin; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Aanerud, Marianne; Fjellbirkeland, Lars (Peer reviewed; Journal article, 2019)
      We have studied the alterations in the use of curative treatment and the outcome for lung cancer patients in Norway 2001–2016. The Cancer Registry of Norway has a practically complete registration of all cancer diagnoses, ...

    • Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study 

      Eide, Inger Johanne; Grut, Harald; Helland, Åslaug; Ekman, Simon; Sørensen, Jens Benn; Hansen, Karin Holmskov; Grønberg, Bjørn Henning; Cicenas, Saulius; Koivunen, Jussi Pekka; Mellemgaard, Anders; Brustugun, Odd Terje (Peer reviewed; Journal article, 2021)
      Introduction Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect ...

    • Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial 

      Rakaee, Mehrdad; Andersen, S.; Giannikou, K.; Paulsen, Erna-Elise; Kilvær, Thomas Karsten; Rasmussen Busund, Lill-Tove; Berg, Thomas; Richardsen, Elin; Lombardi, Ana Paola; Adib, E.; Pedersen, Mona Irene; Tafavvoghi, Masoud; Wahl, Sissel Gyrid Freim; Petersen, R.H.; Bondgaard, A.L.; Yde, C.W.; Baudet, C.; Licht, P.; Lund-Iversen, Marius; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helland, Åslaug; Pøhl, M.; Kwiatkowski, D.J.; Dønnem, Tom (Peer reviewed; Journal article, 2023)
      Background We aim to implement an immune cell score model in routine clinical practice for resected non-small-cell lung cancer (NSCLC) patients (NCT03299478 ). Molecular and genomic features associated with immune ...

    • Mutasjonstesting ved ikke-småcellet lungekreft 

      Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Peer reviewed; Journal article, 2012)
      BAKGRUNN. Epidermal vekstfaktor-reseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer ...

    • Nye sentre skal gi flere kliniske studier i Norge 

      Skoie, Inger Marie; Skogås, Jan Gunnar; Langø, Thomas; Myhr, Kjell-Morten; Myhre, Peder Langeland; Goll, Rasmus; Fretland, Signe Øien; Helland, Åslaug (Journal article; Peer reviewed, 2023)
      Seks NorTrials-sentre for behandlingsforskning er etablert ved universitetssykehusene. Målet er å øke antallet kliniske studier og forbedre pasientbehandlingen.

    • Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials 

      Eide, Inger Johanne Zwicky; Stensgaard, Simone; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Sørensen, Boe Sandahl; Brustugun, Odd Terje (Peer reviewed; Journal article, 2022)
      Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 ...

    • Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study) 

      Eide, Inger Johanne; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Brustugun, Odd Terje (Peer reviewed; Journal article, 2020)
      Objectives In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of ...

    • Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016 

      Brustugun, Odd Terje; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helbekkmo, Nina; Aanerud, Marianne; Grimsrud, Tom Kristian; Helland, Åslaug; Møller, Bjørn; Nilssen, Yngvar; Strand, Trond-Eirik; Solberg, Steinar (Journal article; Peer reviewed, 2018)
      Introduction There have been significant changes in both diagnostic procedures and therapy for lung cancer since the beginning of the millennium. National incidence and survival data from 2000 through 2016 are ...

    • Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people 

      Nilssen, Yngvar; Solberg, Steinar; Brustugun, Odd Terje; Møller, Bjørn; Sundset, Arve; Wahl, Sissel Gyrid Freim; Helland, Åslaug (Peer reviewed; Journal article, 2023)
      OBJECTIVES The incidence of tracheal cancer is low, few clinicians get much experience and the awareness may be low. Recent data on the treatment and outcome are limited. The aim of the present study was to present ...